The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Sanjiv J. Shah et al.|Nature Medicine|2021Cited by 599
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection FractionMichael E. Nassif, John M. Cox, Sheryl L. Windsor et al.|Circulation|2019Cited by 427